[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-for-modal":3,"carousel-press-10":32,"carousel-media-10":161},{"contents":4,"totalCount":31},[5],{"id":6,"createdAt":7,"updatedAt":8,"publishedAt":9,"revisedAt":8,"title":10,"title_en":11,"category":12,"location":17,"thumbnail":26,"publication":30},"t87mogw265","2026-04-20T04:00:37.540Z","2026-04-23T02:08:10.106Z","2026-04-22T03:25:46.315Z","ANベンチャーパートナーズ、2名の新フェロー就任を発表","AN Venture Partners Names Two New Fellows",[13],{"id":14,"title":15,"title_en":16},"press","プレスリリース","Press Release",[18,22],{"id":19,"title":20,"title_en":21},"tokyo","東京","Tokyo",{"id":23,"title":24,"title_en":25},"san_francisco","サンフランシスコ","San Francisco",{"url":27,"height":28,"width":29},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F4ff3de35c77042c7bdd4fc304629b823\u002Ftopimages%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png",1223,2400,null,1,{"contents":33,"totalCount":158,"offset":159,"limit":160},[34,41,53,65,78,97,109,123,135,147],{"id":6,"publishedAt":9,"title":10,"title_en":11,"category":35,"location":37,"thumbnail":40,"publication":30},[36],{"id":14,"title":15,"title_en":16},[38,39],{"id":19,"title":20,"title_en":21},{"id":23,"title":24,"title_en":25},{"url":27,"height":28,"width":29},{"id":42,"publishedAt":43,"title":44,"title_en":45,"category":46,"location":48,"thumbnail":51,"publication":30},"wx2i3ep6i","2026-04-01T04:02:57.435Z","ANベンチャーパートナーズ、山田泰弘氏のアドバイザー就任を発表","AN Venture Partners Announces the Addition of Yasuhiro Yamada as Advisor",[47],{"id":14,"title":15,"title_en":16},[49,50],{"id":23,"title":24,"title_en":25},{"id":19,"title":20,"title_en":21},{"url":52,"height":28,"width":29},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002Faebc848b8e604ee5a8a0d8689ba2f77e\u002F%E3%82%B9%E3%82%AF%E3%83%AA%E3%83%BC%E3%83%B3%E3%82%B7%E3%83%A7%E3%83%83%E3%83%88%202026-03-30%2018.53.45.png",{"id":54,"publishedAt":55,"title":56,"title_en":57,"category":58,"location":60,"thumbnail":61,"publication":30},"gjhhlvri6","2026-02-19T05:42:01.912Z","ウェブサイトリニューアルのお知らせ","Announcement of Website Relaunch",[59],{"id":14,"title":15,"title_en":16},[],{"url":62,"height":63,"width":64},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F4de8c52f5f6741fa89a8c5f2b4627c8a\u002F20260219.png",1081,3200,{"id":66,"publishedAt":67,"title":68,"title_en":69,"category":70,"location":76,"publication":30},"gn2jxk07yg8","2025-10-22T05:17:00.000Z","ANベンチャーパートナーズ、「S2S Japan 2025シンポジウム」を11月13日に開催","AN Venture Partners to Host “S2S Japan 2025 Symposium” on November 13",[71,72],{"id":14,"title":15,"title_en":16},{"id":73,"title":74,"title_en":75},"event","イベント","Event",[77],{"id":19,"title":20,"title_en":21},{"id":79,"publishedAt":80,"title":81,"title_en":82,"category":83,"location":89,"thumbnail":94,"publication":30},"59-10isge","2025-10-21T05:21:00.000Z","クリスタリス・セラピューティクス、痛風治療薬dotinuradの第3相臨床試験を開始し、最初の被験者への投与を実施","Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient",[84,85],{"id":14,"title":15,"title_en":16},{"id":86,"title":87,"title_en":88},"portfolio","出資先企業","Portfolio Companies",[90],{"id":91,"title":92,"title_en":93},"san_diego","サンディエゴ","San Diego",{"url":95,"height":96,"width":96},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F30d367d80c574e06945e6c2657821165\u002Fportfolio-5-.png",1000,{"id":98,"publishedAt":99,"title":100,"title_en":101,"category":102,"location":105,"thumbnail":107,"publication":30},"9mcm6wtsq","2025-09-30T05:14:00.000Z","ANベンチャーパートナーズの新たな投資先企業、 クリスタリス・セラピューティクスが2億500万ドルのシリーズA資金調達を実施","AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment",[103,104],{"id":14,"title":15,"title_en":16},{"id":86,"title":87,"title_en":88},[106],{"id":91,"title":92,"title_en":93},{"url":108,"height":96,"width":96},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002Fc4c18cc1000d453fa20de2c821169c8f\u002Fportfolio-5-.png",{"id":110,"publishedAt":111,"title":112,"title_en":113,"category":114,"location":116,"thumbnail":119,"publication":30},"pgcfhesrey0","2025-08-21T04:00:00.000Z","ANベンチャーパートナーズ、ミカエル・ドルステン氏のアドバイザー就任を発表","AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor",[115],{"id":14,"title":15,"title_en":16},[117,118],{"id":23,"title":24,"title_en":25},{"id":19,"title":20,"title_en":21},{"url":120,"height":121,"width":122},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F8ae3f8c419674e7180e0b2d5109aacd6\u002Ftest03.png",2152,2168,{"id":124,"publishedAt":125,"title":126,"title_en":127,"category":128,"location":131,"thumbnail":133,"publication":30},"rzyiz1gab","2025-07-29T03:55:00.000Z","パー・セラピューティクス、肺動脈性肺高血圧症の革新的治療法の開発に向けて 1,400万ドルのシード資金を調達","Pahr Therapeutics raises $14 million seed financing to pursue innovative treatments for Pulmonary Arterial Hypertension",[129,130],{"id":14,"title":15,"title_en":16},{"id":86,"title":87,"title_en":88},[132],{"id":19,"title":20,"title_en":21},{"url":134,"height":96,"width":96},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F3aca3545012a4db0a5905d77f703b5f3\u002Fportfolio-4-.png",{"id":136,"publishedAt":137,"title":138,"title_en":139,"category":140,"location":142,"thumbnail":145,"publication":30},"thv3ofnu3of","2025-07-02T03:21:00.000Z","ANベンチャーパートナーズ、1号ファンドを2億ドルでファイナルクローズ","AN Venture Partners Announces Final Close of $200M Fund I",[141],{"id":14,"title":15,"title_en":16},[143,144],{"id":23,"title":24,"title_en":25},{"id":19,"title":20,"title_en":21},{"url":146,"height":29,"width":29},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F11c568c87b514218b12af4637a2675cf\u002Fthumbnail.jpg",{"id":148,"publishedAt":149,"title":150,"title_en":151,"category":152,"location":154,"thumbnail":156,"publication":30},"yno90r2-vk","2025-06-15T05:34:00.000Z","ANベンチャーパートナーズ、ポーラ・シュルタイスのアソシエイト昇格と3名のフェローの任命を発表","AN Venture Partners Promotes Paula Schultheiss to Associate and Names Three New Fellows",[153],{"id":14,"title":15,"title_en":16},[155],{"id":19,"title":20,"title_en":21},{"url":157,"height":121,"width":122},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F88fc9919aa68476bb73482d884278cea\u002Ftest02.png",23,0,10,{"contents":162,"totalCount":291,"offset":159,"limit":160},[163,180,193,204,219,233,243,255,268,280],{"id":164,"publishedAt":165,"title_en":166,"category":167,"location":172,"publication":173,"external_url":179},"7c7pfm40x_f","2025-12-20T08:14:00.000Z","Raising the sun: Japan biotech looks to level up",[168],{"id":169,"title":170,"title_en":171},"media","メディア","Media",[],{"publication":174,"publication_en":174,"image":175},"BioCentury",{"url":176,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F425c3dfdc28c455fb977cf746683d987\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png",1452,3000,"https:\u002F\u002Fwww.biocentury.com\u002Farticle\u002F657543",{"id":181,"publishedAt":182,"title":183,"category":184,"location":186,"publication":187,"external_url":192},"oe2rg6zrb9jh","2025-12-01T08:12:00.000Z","S2S Japanシンポジウム、mRNA標的低分子薬や腫瘍溶解性ペプチドなど日本発シーズを紹介",[185],{"id":169,"title":170,"title_en":171},[],{"publication":188,"publication_en":189,"image":190},"日経バイオテクONLINE","Nikkei Biotech online",{"url":191,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F7926815a791a46929f3a86d7a589390e\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fbio.nikkeibp.co.jp\u002Fatcl\u002Fnews\u002Fp1\u002F25\u002F11\u002F26\u002F14018\u002F",{"id":194,"publishedAt":195,"title":196,"category":197,"location":200,"publication":201,"external_url":203},"3s-sxbod0rld","2025-09-26T08:11:00.000Z","ベンチャー探訪  Pahr Therapeutics社、肺動脈性肺高血圧症にAHRを制御する治療薬を開発へ",[198,199],{"id":169,"title":170,"title_en":171},{"id":86,"title":87,"title_en":88},[],{"publication":188,"publication_en":189,"image":202},{"url":191,"height":177,"width":178},"https:\u002F\u002Fbio.nikkeibp.co.jp\u002Fatcl\u002Fcolumn\u002F16\u002F021500017\u002F091800379\u002F",{"id":205,"publishedAt":206,"title":207,"category":208,"location":211,"thumbnail":212,"publication":213,"external_url":218},"zzk7i5irf9g","2025-09-18T08:10:00.000Z","日本発なのに米国企業へ“転生”続々、創薬スタートアップ　「100均問題」足かせ",[209,210],{"id":169,"title":170,"title_en":171},{"id":86,"title":87,"title_en":88},[],{"url":146,"height":29,"width":29},{"publication":214,"publication_en":215,"image":216},"日経ビジネス電子版","Nikkei Business Online",{"url":217,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F17f3e27d4f994f29b6313f661f253760\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fbusiness.nikkei.com\u002Fatcl\u002Fgen\u002F19\u002F00784\u002F091600006\u002F",{"id":220,"publishedAt":221,"title":222,"category":223,"location":226,"publication":227,"external_url":232},"xnq0bhkrr","2025-07-29T08:09:00.000Z","国循発ベンチャー、1400万ドルを調達　　パー・セラピューティクス、PAHの治療法開発へ",[224,225],{"id":169,"title":170,"title_en":171},{"id":86,"title":87,"title_en":88},[],{"publication":228,"publication_en":229,"image":230},"日刊薬業電子版","Nikkan Yakugyo Online",{"url":231,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F65e8fad94e1f4a0da1fc11e4c435b60f\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fnk.jiho.jp\u002Farticle\u002F200815",{"id":234,"publishedAt":235,"title":236,"category":237,"location":239,"publication":240,"external_url":242},"d9evgqi02ya","2025-07-04T08:08:00.000Z","日米に拠点を持つVCの米AN Venture Partners社、第1号ファンドを2億ドルでクローズ",[238],{"id":169,"title":170,"title_en":171},[],{"publication":188,"publication_en":189,"image":241},{"url":191,"height":177,"width":178},"https:\u002F\u002Fbio.nikkeibp.co.jp\u002Fatcl\u002Fnews\u002Fp1\u002F25\u002F07\u002F03\u002F13489\u002F",{"id":244,"publishedAt":245,"title_en":246,"category":247,"location":249,"publication":250,"external_url":254},"lmn3deak8a9s","2025-07-02T08:14:00.000Z","Biotech VC raises $200M to focus on Japan’s ‘untapped source’ of innovation",[248],{"id":169,"title":170,"title_en":171},[],{"publication":251,"publication_en":251,"image":252},"Fierce Biotech",{"url":253,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002Fdfeb22c8eea4425c81807273f7cbe5b3\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Fbiotech-vc-raises-200m-focus-japans-untapped-source-innovation",{"id":256,"publishedAt":257,"title":258,"category":259,"location":261,"publication":262,"external_url":267},"ynm58_as2w","2025-07-02T08:05:00.000Z","国内最大の創薬ファンド　米ANV、日本向け300億円調達 ",[260],{"id":169,"title":170,"title_en":171},[],{"publication":263,"publication_en":264,"image":265},"日本経済新聞 電子版","Nikkei Online",{"url":266,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002Ff63b1cb366b644a4b56779e2adca9724\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fwww.nikkei.com\u002Farticle\u002FDGXZQOUB01BFB0R00C25A7000000\u002F",{"id":269,"publishedAt":270,"title_en":271,"category":272,"location":274,"publication":275,"external_url":279},"vrme4xih52d4","2025-07-01T08:13:00.000Z","AN Venture Partners lines up $200M freshman fund to champion Japanese innovation ",[273],{"id":169,"title":170,"title_en":171},[],{"publication":276,"publication_en":276,"image":277},"ENDPOINTS News",{"url":278,"height":177,"width":178},"https:\u002F\u002Fimages.microcms-assets.io\u002Fassets\u002F58856f3aa62e43fca2f7f42b53ca0e2c\u002F56775aa10f8b40559af53c1f6b9a44b0\u002FMedia%20%E3%81%AE%E3%82%B3%E3%83%92%E3%82%9A%E3%83%BC.png","https:\u002F\u002Fendpoints.news\u002Fan-venture-partners-lines-up-200m-freshman-fund-to-champion-japanese-innovation\u002F",{"id":281,"publishedAt":282,"title":283,"category":284,"location":287,"publication":288,"external_url":290},"7uhlfwew4xld","2025-04-17T08:03:00.000Z","遺伝情報、コピペで書き換える分子　解析で難病治療に光",[285,286],{"id":169,"title":170,"title_en":171},{"id":86,"title":87,"title_en":88},[],{"publication":263,"publication_en":264,"image":289},{"url":266,"height":177,"width":178},"https:\u002F\u002Fwww.nikkei.com\u002Farticle\u002FDGXZQOSG2595J0V20C25A2000000\u002F?msockid=0aa4752dbd9860212dbc6133bc7261a2",20]